

Value analysis packet

OsteoCool[™] 2.0 radio frequency (RF) ablation for the treatment of painful bone tumors



CONTENTS

Product introduction
Clinical data
Ablation zones
Billing and coding information9
Ordering information
Notes
Reference information
Safety information

PRODUCT INTRODUCTION

A minimally invasive treatment for painful bone tumors

OsteoCool[™] 2.0 radio frequency (RF) ablation

About cancer pain

When cancer metastasizes, or moves into surrounding bone, it can affect patients' quality of life, producing complications such as pain, fractures, and decreased mobility¹ – making every day a challenge. Bone metastases can also cause mood changes such as depression and anxiety.²

Patients may feel cancer pain from:

- Cancer treatment such as surgery, radiation, and chemotherapy³

Patients with metastatic bone cancer may be treated with conventional therapies such as opioids, chemotherapy, or radiation therapy for pain palliation.

However, many cancer patients are left with inadequate treatment or undermanaged pain control because these conventional therapies didn't work for them,⁴ are too slow acting, or cause unacceptable side effects.⁵

In these cases, physicians may use radiofrequency ablation to help treat painful bone tumors.

• Tumor growth that invades or presses on bones, nerves, the spinal cord, or body organs³

About OsteoCool[™] 2.0 radiofrequency ablation (RF)

Medtronic offers OsteoCool™ 2.0 RF ablation to help treat painful bone tumors. RF ablation uses alternating, lowpower current to generate heat during the procedure. The heat is delivered by a probe to the tumor to intentionally dry out and kill cancerous cells.

Accelerated results. Dependable outcomes.

OsteoCool™ 2.0 RF ablation system delivers the same proven outcomes - faster. Featuring the same patented internally cooled probe design that reduces the risk of charring, the OsteoCool[™] 2.0 system delivers **powerful**, predictable, and proven pain relief.





Powerful

- Allows the use of four probes simultaneously, enabling ablation of two vertebral bodies at once or overlap ablation zones to create larger lesions in extraspinal applications.
- Features 100W system the most ablative power on the market.⁶⁻⁸

Predictable

- Independent channel control adds the convenient ability to stop and start channels individually.
- Internally cooled probes reduces the risk of charring without introducing ionic solutions into the ablation zone.

aduonic

Meditonic

Meditonic

Meditionic

faster than the OsteoCool[™] 1.0 system^{9†}

Ablate lesions up to

†Bench testing may not be indicative of clinical results.



• Four available sizes to tailor the ablation size to **individual patient needs**.

Proven

• Backed by OPuS One, the largest study on RF ablation in bone metastases.¹⁰ • Time-tested with over 18,000 patients receiving OsteoCool™ procedures over the last six years. • Trusted – more than 1,400 hospitals use OsteoCool™ technology to treat patients with bone metastases.

CLINICAL DATA

Radiofrequency Ablation Provides Rapid and Durable Pain Relief for the Palliative Treatment of Lytic Bone Metastases Independent of Radiation Therapy: Final Results from the OsteoCool Tumor Ablation Post-Market Study.

Levy J, David E, Hopkins T, et al. Cardiovasc Intervent Radiol. 2023;46(5):600-609. doi:10.1007/s00270-023-03417-x

OBJECTIVE

To evaluate the effectiveness of radiofrequency (RF) ablation as measured by change in worst pain score from baseline to 3 mo after RF ablation for the palliative treatment of painful bone metastases.

DESIGN

The OsteoCool[™] tumor ablation post-market study (OPuS One) was a prospective, multi-national, single-arm study to investigate safety and effectiveness of radiofrequency ablation (RFA) for palliation of painful lytic bone metastases with 12 months of follow-up. RFA has demonstrated effective palliation of osseous metastases in small clinical studies with short-term follow-up; however, a long-term assessment with robust subject numbers is lacking.

RESULTS

206 subjects were treated with RFA at 15 institutions in OPuS One. Worst pain, average pain, pain interference and quality of life significantly improved at all visits starting 3 days post-RFA and sustained to 12 months (P < 0.0001). Post hoc analysis found neither systemic chemotherapy nor local radiation therapy at the index site of RFA influenced worst pain, average pain, or pain interference. Six subjects had device/procedure-related adverse events.

CONCLUSIONS

RFA for lytic metastases provides rapid (within 3 days) and statistically significant pain and quality of life improvements with sustained long-term relief through 12 months and a high degree of safety, independent of radiation.

https://pubmed.ncbi.nlm.nih.gov/37012392/

+"Clinically meaningful" indicates that there was at least a 2-point change in worst pain from one follow-up visit to the next.


Clinical data: OPuS One study

OPuS One is the largest prospective study to date in RF ablation for bone metastases. It is important to highlight that the original OsteoCool[™] system was the only RF ablation

technology evaluated in the OPuS One study.


Key takeaways

OsteoCool™ RF ablation provides pain relief that is swift, significant, and sustained.




Significant

- Improvement in worst pain at all visits
- Improvement in QOL a key additional measurement given the fact that cancer patients are living longer with their disease.¹¹



Swift


- Pain relief was as quick as 3 days post-procedure
- 60% of patients had clinically meaningful pain relief at 3 days post-procedure
- Beneficial for patients who are considered end of life given their advanced stage of disease.



7 | OsteoCool[™] 2.0 radio frequency (RF) ablation | Value analysis packet

The OsteoCool[™] RF ablation probes are bipolar and cooled internally with water. Probes are 17 G, available with 7 mm, 10 mm, 15 mm, and 20 mm active ablation tips, and may be used with a variety of cannula sizes. A thermocouple monitors the temperature around the distal tip of the probe. The ablation time for each size probe varies. When a probe is plugged into the connector hub, the time is automatically set on the generator.

At a target temperature of 70 C at the distal thermocouple, a probe will ablate for a standardized time and yields the following ablation zone sizes:



The OsteoCool™ independent thermocouple monitors surrounding tissue temperature. The 28 G thermocouple comes with a 20 G spinal needle.

The OsteoMAPSM technique relies on an OsteoCool™ bone access kit to access bone percutaneously. Access kits are available in 8 G, 10 G, and 13 G, and include an introducer (cannula plus trocar tip stylet) and a bone access drill. The drill is color-coded to correspond with different ablation probe sizes.

BILLING AND CODING INFORMATION

Hospital outpatient coding and payment

Effective January 1, 2024 - December 31, 2024

RFA

CPT codeª	Description	APC ^f	APC level	Status indicator ^{f,8}	Relative weight ^f	Medicare national average ^{f,g}
20982	20982 Ablation therapy for reduction or eradication of 1 or more bone tumors (eg, metastasis), including adjacent soft tissue when involved by tumor extension, percutaneous, including imaging guidance when performed, radiofrequency ⁴	5115	Level 5	J1	143.6551	\$12,553

RFA with Vertebroplasty

considered adjunctive and no separate payment is made.

CPT code ^a	Description	APC ^f	APC level	Status indicator ^{f,8}	Relative weight ^f	Medicare national average ^{f,g}
20982	20982 Ablation therapy for reduction or eradication of 1 or more bone tumors (eg, metastasis), including adjacent soft tissue when involved by tumor extension, percutaneous, including imaging guidance when performed, radiofrequency ⁴		Level 5	J1	143.6551	\$12,553
Plus						
22510	Percutaneous vertebroplasty (bone biopsy included when performed), 1 vertebral body, unilateral or bilateral injection, inclusive of all imaging guidance; cervicothoracic		Level 3	J1	-	-
22511	Lumbosacral ⁵	5113	Level 3	J1	-	-
+22512	each additional cervicothoracic or lumbosacral vertebral body ⁶	-	_	Ν	-	-

RFA with Kyphoplasty

RFA code 20982 is assigned to a higher ranked C-APC. Any VP/BKP performed during the same encounter is considered adjunctive and no separate payment is made.

CPT codeª	Description	APC ^f	APC level	Status indicator ^{f,8}	Relative weight ^f	Medicare national average ^{f,g}
20982	20982 Ablation therapy for reduction or eradication of 1 or more bone tumors (eg, metastasis), including adjacent soft tissue when involved by tumor extension, percutaneous, including imaging guidance when performed, radiofrequency ⁴	5115	Level 5	J1	143.6551	\$12,553
Plus						
22513	Percutaneous vertebral augmentation, including cavity creation (fracture reduction and bone biopsy included when performed) using mechanical device (eg, kyphoplasty), 1 vertebral body, unilateral or bilateral cannulation, inclusive of all imaging guidance; thoracic	5114	Level 4	J1	-	-
22514	Lumbar	5114	Level 4	J1	-	-
+22515	each additional thoracic or lumbar vertebral body ⁶	-	-	Ν	-	-


Note: In CPT, the kyphoplasty codes involve a separate and distinct mechanical device, eg, an inflatable balloon or tamp, used in an intentional manner to further develop the defect into a purposeful cavity prior to cement injection.

Note: Although codes for vertebroplasty may be assigned, relative weight and payment are not shown below because RFA code 20982 is assigned to a higher ranked C-APC. Any VP/BKP performed during the same encounter is

Note: Although codes for Kyphoplasty may be assigned, relative weight and payment are not shown below because

ORDERING INFORMATION

OsteoCool[™] bone access kits



OsteoCool[™] single probe kits


Single probe ablation sizing

OCP107 7 mm Probe active tip	Medtronic	·	
5:30 minutes Accelerated timir	ngs		169 mm
OCP110	Medtronic	-	
10 mm Probe active tip		L	
6:00 minutes Accelerated timi	igs		173 mm
OCP115	Medtronic	œ	
15 mm			
Probe active tip 8:00 minutes Accelerated timir	igs		179 mm
OCP120		-	
20 mm	Medtronic		
Probe active tip 11:30 minutes Accelerated timir	igs		185 mm

Illustrations above show measurement from top of cannula to tip of probe.



OsteoCool[™] independent




Each kit contains: (1) OsteoCool™ RF ablation probe and (1) OsteoCool™ RF ablation burette



11 | OsteoCool[™] 2.0 radio frequency (RF) ablation | Value analysis packet

OsteoCool™ 2-probe kits

Capital equipment





Dual-probe ablation zones

OsteoCool™ pump OC02-100

OC01-100



8 mm

OsteoCool™ burette



Each kit contains: (2) OsteoCool™ RF ablation probes and (2) OsteoCool™ RF ablation burette

OsteoCool[™] independent thermocouple 28 ga, 180 mm





OsteoCool™ probe connector hub OC04-100



REFERENCE INFORMATION

- Targeting metastatic bone pain. Eur J Cancer. 2017;71:80-94.
- 2. Spiegel D, et al. Pain and depression in patients with cancer. Cancer. 1994;74:2570-2578.
- physical-side-effects/pain/facts-about-cancer-pain.html.
- Anselmetti, et al. Treatment of Extraspinal Painful Bone Metastases with Percutaneous Cementoplasty: A 4. Prospective Study of 50 Patients. Cardiovasc Intervent Radiol. 2008;31:1165-1173.
- MRI. 2009;30(2):78-90.
- 6. Clarivate Interventional Oncology Devices Market Insights United States report, December 2022.
- 7. Stryker OptaBlate™* RF Generator System IFU 700001075365 Rev-AC.
- 8. Merit MetaSTAR[™]* RF Generator IFU 403321001_001.
- 03417-x. Epub 2023 Apr 3. PMID: 37012392; PMCID: PMC10156864.
- 11. https://www.cancer.gov/about-cancer/understanding/statistics

SAFETY INFORMATION

- Intended for palliative treatment in spinal procedures by ablation of metastatic malignant lesions in a vertebral body
- Coagulation and ablation of tissue in bone during surgical procedures including palliation of pain associated with metastatic lesions involving bone in patients who have failed or are not candidates for standard therapy
- Ablation of benign bone tumors such as osteoid osteoma

Risks

- As a consequence of electrosurgery, damage to surrounding tissue through iatrogenic injury could occur
- Pulmonary embolism

1. von Moos R, Costa L, Ripamonti CI, Niepel D, Santini D. Improving quality of life in patients with advanced cancer:

3. American Cancer Society. Facts About Cancer Pain. https://www.cancer.org/treatment/ treatments-and-side-effects/

5. Sabharwal T, Katsanos K, Buy X, Gangi A. Image-guided ablation therapy of bone tumors. Semin Ultrasound CT

9. Based on internal data: ETR 30101200, OsteoCool 2.0 Lesion Validation Test Report, 20 samples. 2023. 10. Levy J, David E, Hopkins T, Morris J, Tran ND, Farid H, Massari F, O'Connell WG, Vogel A, Gangi A, Sunenshine P, Dixon R, Von der Höh N, Bagla S. Radiofrequency Ablation Provides Rapid and Durable Pain Relief for the Palliative Treatment of Lytic Bone Metastases Independent of Radiation Therapy: Final Results from the OsteoCool Tumor Ablation Post-Market Study. Cardiovasc Intervent Radiol. 2023 May;46(5):600-609. doi: 10.1007/s00270-023-



710 Medtronic Parkway Minneapolis, MN 55432-5604 USA Tel: 763-514-4000

medtronic.com

©2024 Medtronic. Medtronic, Medtronic logo, and Engineering the extraordinary are trademarks of Medtronic. All other brands are trademarks of a Medtronic company. UC202409584 EN